Claims
- 1. A medical device comprising:
a structure adapted for introduction into a patient, wherein the structure comprises a surface; a layer of surfactant adsorbed on the surface of the medical device, wherein the surfactant on the surface of the medical device is substantially non-activating or deactivating to the complement cascade as compared to the non-coated surface of the medical device.
- 2. The medical device of claim 1, wherein the medical device is selected from the group consisting of balloon catheters, A/V shunts, vascular grafts, stents, pacemaker leads, pacemakers, heart valves, catheters, and guide wires.
- 3. The medical device of claim 1, wherein the medical device is selected from the group consisting of cardiopulmonary bypass device, plasmapheresis device, plateletpheresis device, leukopheresis device, LDL removal device, hemodialysis device, hemofiltration filters, ultrafiltration device, hemoperfusion device, blood oxygenator, blood pump, blood sensor, and tubing used to carry blood which is then returned to the patient.
- 4. The medical device according to claim 1, wherein the surfactant is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4).
- 5. The medical device of claim 1, wherein the surfactant comprises a block copolymer.
- 6. The medical device of claim 1, wherein the surfactant comprises a block copolymer comprising hydrophobic regions and hydrophilic regions.
- 7. The medical device of claim 1, wherein the surfactant comprises a PLURONICS block copolymer.
- 8. The medical device of claim 1, wherein the surfactant comprises a therapeutic entity attached thereto.
- 9. The medical device of claim 8, wherein the surfactant comprises a compound with the formula:
- 10. The medical device of claim 9, wherein the therapeutic entity is a protein, protein fragment, peptide, oligonucleotide, carbohydrate, proteoglycan, antibody or drug.
- 11. The medical device of claim 9, wherein the therapeutic entity is a regulator of complement activation or an active domain thereof.
- 12. The medical device of claim 9, wherein the regulator of complement activation is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4), C4 binding protein (C4bp), complement receptor 1 (CR1), compstatin, decay-accelerating factor (DAF), membrane cofactor protein (MCP), vaccinia virus complement control protein (VCP) and small pox inhibitor of complement enzymes (SPICE).
- 13. The medical device of claim 9, wherein the copolymer comprises polymer units selected from the group consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO), PEO and polybutadiene, PEO and poly(N-acetylethyleneimine), PEO and phenyl boronic acid, PEO and polyurethane, PEO and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
- 14. The medical device of claim 9, wherein the hydrophilic domain comprises polyethylene oxide.
- 15. The medical device of claim 9, wherein the hydrophobic domain comprises a polymer unit selected from the group consisting of polypropylene oxide (PPO), polybutadiene, poly(N-acetylethyleneimine), phenyl boronic acid, polyurethane, polymethylmethacrylate (PMMA), and polydimethyl sulfoxide.
- 16. A method for coating a medical device with a surface coating comprising:
providing the medical device with a surface; providing a surfactant; adsorbing the surfactant on the surface of the medical device; wherein the surfactant on the surface of the medical device is substantially non-activating or deactivating to the complement cascade as compared to the non-coated surface of the medical device.
- 17. The method of claim 16, wherein the medical device is selected from the group consisting of balloon catheters, A/V shunts, vascular grafts, stents, pacemaker leads, pacemakers, heart valves, catheters, and guide wires.
- 18. The method of claim 16, wherein the medical device is selected from the group consisting of cardiopulmonary bypass device, plasmapheresis device, plateletpheresis device, leukopheresis device, LDL removal device, hemodialysis device, hemofiltration filters, ultrafiltration device, hemoperfusion device, blood oxygenator, blood pump, blood sensor, and tubing used to carry blood which is then returned to the patient.
- 19. The method according to claim 16, wherein the surfactant is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4).
- 20. The method of claim 16, wherein the surfactant is adsorbed on the surface of the medical device with a block copolymer.
- 21. The method of claim 16, wherein the surfactant is adsorbed on the surface of the medical device with a block copolymer comprising hydrophobic regions and hydrophilic regions.
- 22. The method of claim 16, wherein the surfactant is adsorbed on the surface of the medical device with a PLURONICS block copolymer.
- 23. The method of claim 16, wherein the surfactant comprises a therapeutic entity attached thereto.
- 24. The method of claim 23, wherein the surfactant comprises a compound with the formula:
- 25. The method of claim 24, wherein the therapeutic entity is a protein, protein fragment, peptide, oligonucleotide, carbohydrate, proteoglycan, antibody or drug.
- 26. The method of claim 24, wherein the therapeutic entity is a regulator of complement activation or an active domain thereof.
- 27. The method of claim 26, wherein the regulator of complement activation is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4), C4 binding protein (C4bp), complement receptor 1 (CR1), compstatin, decay-accelerating factor (DAF), membrane cofactor protein (MCP), vaccinia virus complement control protein (VCP) and small pox inhibitor of complement enzymes (SPICE).
- 28. The method of claim 24, wherein the copolymer comprises polymer units selected from the group consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO), PEO and polybutadiene, PEO and poly(N-acetylethyleneimine), PEO and phenyl boronic acid, PEO and polyurethane, PEO and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
- 29. The method of claim 24, wherein the hydrophilic domain comprises polyethylene oxide.
- 30. The method of claim 24, wherein the hydrophobic domain comprises a polymer unit selected from the group consisting of polypropylene oxide (PPO), polybutadiene, poly(N-acetylethyleneimine), phenyl boronic acid, polyurethane, polymethylmethacrylate (PMMA), and polydimethyl sulfoxide.
- 31. A compound for coating a medical device with the formula:
- 32. The compound according to claim 31, wherein the therapeutic entity is a protein, protein fragment, peptide, oligonucleotide, carbohydrate, proteoglycan, antibody or drug.
- 33. The compound according to claim 31, wherein the therapeutic entity is a regulator of coagulation or an active domain thereof.
- 34. The compound according to claim 33, wherein the therapeutic entity is an antibody.
- 35. The compound according to claim 31, wherein the therapeutic entity is a regulator of complement activation or an active domain thereof.
- 36. The compound according to claim 35, wherein the regulator of complement activation is selected from the group consisting of factor H, factor H like protein 1 (FHL-1), factor H related proteins (FHR-3, FHR-4), C4 binding protein (C4bp), complement receptor 1 (CR1), compstatin, decay-accelerating factor (DAF), membrane cofactor protein (MCP), vaccinia virus complement control protein (VCP) and small pox inhibitor of complement enzymes (SPICE).
- 37. The compound according to claim 31, wherein the copolymer comprises polymer units selected from the group consisting of polyethylene oxide (PEO) and polypropylene oxide (PPO), PEO and polybutadiene, PEO and poly(N-acetylethyleneimine), PEO and phenyl boronic acid, PEO and polyurethane, PEO and polymethylmethacrylate (PMMA), and PEO and polydimethyl sulfoxide.
- 38. The compound according to claim 31, wherein the hydrophilic domain comprises polyethylene oxide.
- 39. The compound according to claim 31, wherein the hydrophobic domain comprises a polymer unit selected from the group consisting of polypropylene oxide (PPO), polybutadiene, poly(N-acetylethyleneimine), phenyl boronic acid, polyurethane, polymethylmethacrylate (PMMA), and polydimethyl sulfoxide.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent application No. 60/420,390, filed Oct. 21, 2002, which is entirely incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60420390 |
Oct 2002 |
US |